Weight Loss Injections Online: What Clinical Evidence Actually Shows

What the trials established, and why UK regulators approved these medicines

The case for GLP-1 and dual GIP/GLP-1 medicines rests on some of the largest randomised controlled trials in obesity research. SURMOUNT-1, published in the New England Journal of Medicine, enrolled 2,539 adults with obesity and no diabetes. Those who received tirzepatide 15mg for 72 weeks lost an average of around 20–21% of their body weight. The STEP 1 trial did the same for semaglutide 2.4mg over 68 weeks, finding roughly 15% average reduction. Both figures came alongside a reduced-calorie diet and increased physical activity, not in isolation.

These results informed NICE's recommendations for both medicines. NICE TA1026 (tirzepatide) and TA875 (semaglutide) set out specific BMI and comorbidity thresholds, reflecting the clinical evidence that benefit is clearest in people with meaningful excess weight and related health conditions. The MHRA licensed both as prescription-only medicines, meaning a qualified prescriber (not a website algorithm) must decide whether treatment is appropriate for you.

For people researching the best place to get weight loss injections online, that statutory framework is the most important starting point. The medicine is only part of the picture; the clinical assessment around it is what makes it safe.

Who qualifies, and what the assessment actually covers

Under their UK licences, both Mounjaro and Wegovy are indicated for adults with a BMI of 30 or above, or from 27 upwards when at least one weight-related condition is present. Qualifying conditions include type 2 diabetes, hypertension, dyslipidaemia, obstructive sleep apnoea and cardiovascular disease. NICE's recommendations for NHS access add stricter thresholds, but private prescribing follows the licensed criteria.

A thorough assessment goes further than a BMI number. Prescribers at regulated online services will ask about your medical history, current medicines, previous attempts at weight management and any contraindications listed in the prescribing information. Pregnancy, breastfeeding and a history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 are among the conditions that rule these medicines out entirely. For women of childbearing age taking an oral contraceptive, tirzepatide requires the addition of a non-oral contraceptive method for the first four weeks of treatment and for four weeks after each dose increase, because gastric slowing can reduce pill absorption.

If you want a clear picture of how those criteria apply to you specifically, our clinical team reviews every consultation personally. That is where the eligibility question gets a real answer.

Side effects the evidence reports, and when to seek help quickly

The dominant side-effect profile for both medicines is gastrointestinal. Nausea, loose stools, constipation, reflux, burping and fatigue are the most commonly reported, particularly in the first weeks of treatment or after a dose increase. They are not universal, and for most people they ease as the body adjusts. Drinking enough water, eating smaller portions and pacing meals all help.

A smaller number of people experience more serious effects. In January 2026, the MHRA issued a Drug Safety Update specifically for GLP-1 medicines, flagging acute pancreatitis as an infrequent but potentially serious risk. The warning sign to act on immediately is severe stomach pain that persists and radiates to the back, with or without vomiting, that needs urgent medical attention, not a wait-and-see approach. Suspected side effects, including those from counterfeit products, can be reported directly through the MHRA Yellow Card scheme.

Injection-site reactions (redness, mild swelling) are common and usually brief. Rotating between the abdomen, thigh and upper arm helps. Keeping the pen refrigerated between uses is essential; the exact room-temperature window for each product is in the Patient Information Leaflet, because it differs between Mounjaro and Wegovy and is not something to estimate.

What a legitimate online supply looks like in practice

Here is a detail that often surprises people: the practical experience of receiving these medicines through a regulated online pharmacy is more mundane than the hype around them suggests. A plain, unbranded box arrives via DPD with a tracking link on your phone. Inside is the pen, the Patient Information Leaflet and everything you need to start, no theatre, no hustle, no expiry-date pressure.

What makes an online service legitimate is verifiable. The GPhC pharmacy register lists every registered UK pharmacy by name, address and registration number, anyone can check. A service that cannot be found there is not operating legally. The MHRA has warned repeatedly about counterfeit weight-loss pens sold online and through social media; fake pens seized in enforcement raids have contained insulin rather than the labelled medicine, with serious consequences for people who injected them. If you are based in the capital and exploring your options, our page on weight loss injections in London explains how to access treatment through a properly registered service in your area. The rule of thumb: if a seller offers these medicines without a clinical assessment, that is both a legal breach and a safety warning.

For a closer look at what the assessment and prescription process involves at a properly registered service, this guide covers the legal route in detail. If you are comparing options and want to understand what different providers actually include in their pricing, the cost breakdown page explains what a transparent price should cover. When you are ready to find out whether you qualify, you can speak to our prescribers through a free consultation, reviewed the same day by a real clinician, not software, as part of what we consider the best online weight loss injection program for people who want proper clinical oversight from start to finish.